CIK 0002036042 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Sionna Therapeutics, Inc.
Sign in to watch- Ticker
- SION
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-819-2020
- Business address
- 21 HICKORY DRIVE, SUITE 500, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $21,835,018
- in 1 filing
Net −$21,835,018. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-17 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −3,415,011 | $6.32 | $21.6M | 3,482,612 |
| 2026-09-17 | RA CAPITAL MANAGEMENT, L.P. Director | Sale | −33,800 | $7.46 | $252K | 3,448,812 |
| 2026-09-17 | Fitzpatrick Jennifer CLO and Head of Program Mgmt. | Grant or award | +28,133 | 28,133 | ||
| 2026-09-17 | Fitzpatrick Jennifer CLO and Head of Program Mgmt. | Grant or award | +28,132 | 56,265 | ||
| 2026-09-17 | Fitzpatrick Jennifer CLO and Head of Program Mgmt. | Grant or award · Non-Qualified Stock Option (right to buy) | +103,140 | 103,140 | ||
| 2026-09-17 | Fitzpatrick Jennifer CLO and Head of Program Mgmt. | Returned to the company · Non-Qualified Stock Option (right to buy) | −103,140 | 0 | ||
| 2026-09-17 | McKee Charlotte CMO and Head of R&D | Grant or award | +50,000 | 78,415 | ||
| 2026-09-17 | McKee Charlotte CMO and Head of R&D | Grant or award | +50,000 | 128,415 | ||
| 2026-09-17 | McKee Charlotte CMO and Head of R&D | Grant or award · Non-Qualified Stock Option (right to buy) | +155,700 | 155,700 | ||
| 2026-09-17 | McKee Charlotte CMO and Head of R&D | Returned to the company · Non-Qualified Stock Option (right to buy) | −155,700 | 0 | ||
| 2026-09-17 | Ridloff Elena CFO and CBO | Grant or award | +47,269 | 85,801 | ||
| 2026-09-17 | Ridloff Elena CFO and CBO | Grant or award | +47,268 | 133,069 | ||
| 2026-09-17 | Ridloff Elena CFO and CBO | Grant or award · Non-Qualified Stock Option (right to buy) | +165,440 | 165,440 | ||
| 2026-09-17 | Ridloff Elena CFO and CBO | Returned to the company · Non-Qualified Stock Option (right to buy) | −165,440 | 0 | ||
| 2026-09-17 | Cloonan Michael President & CEO | Grant or award | +109,025 | 656,368 | ||
| 2026-09-17 | Cloonan Michael President & CEO | Grant or award | +109,025 | 765,393 | ||
| 2026-09-17 | Cloonan Michael President & CEO | Grant or award · Non-Qualified Stock Option (right to buy) | +436,100 | 436,100 | ||
| 2026-09-17 | Cloonan Michael President & CEO | Returned to the company · Non-Qualified Stock Option (right to buy) | −436,100 | 0 | ||
| 2026-07-07 | Thompson Peter A. Director | Sale 10b5-1 | −85,918 | $44.86 | $3.9M | 2,469,959 |
| 2026-07-07 | ORBIMED ADVISORS LLC Director | Sale 10b5-1 | −85,918 | $44.86 | $3.9M | 2,469,959 |
Page 1 of 15 · 284 trades